EDIT Editas Medicine Inc
Price (delayed)
$1.18
Market cap
$97.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.88
Enterprise value
$58.84M
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a
Highlights
The debt has soared by 153% YoY and by 140% from the previous quarter
EDIT's equity has dropped by 62% year-on-year and by 24% since the previous quarter
Key stats
What are the main financial stats of EDIT
Market
Valuations
Earnings
Shares outstanding
82.98M
Market cap
$97.91M
Enterprise value
$58.84M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.73
Price to sales (P/S)
3.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.82
Revenue
$32.31M
Gross profit
$32.31M
Operating income
-$251.15M
Net income
-$237.09M
EBIT
-$251.16M
EBITDA
-$245.35M
Free cash flow
-$219.11M
Per share
Balance sheet
Liquidity
EPS
-$2.88
EPS diluted
-$2.88
Free cash flow per share
-$2.66
Book value per share
$1.63
Revenue per share
$0.39
TBVPS
$4.15
Total assets
$341.59M
Total liabilities
$207.32M
Debt
$92.47M
Equity
$134.27M
Working capital
$212.09M
Debt to equity
0.69
Current ratio
3.75
Quick ratio
3.71
Net debt/EBITDA
0.16
Margins
Efficiency
Dividend
EBITDA margin
-759.3%
Gross margin
100%
Net margin
-733.7%
Operating margin
-777.2%
Return on assets
-63.5%
Return on equity
-113.4%
Return on invested capital
-96%
Return on capital employed
-95%
Return on sales
-777.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EDIT stock price
How has the Editas Medicine stock price performed over time
Intraday
4.42%
1 week
-7.09%
1 month
-38.54%
1 year
-82.82%
YTD
-7.09%
QTD
1.72%
Financial performance
How have Editas Medicine's revenue and profit performed over time
Revenue
$32.31M
Gross profit
$32.31M
Operating income
-$251.15M
Net income
-$237.09M
Gross margin
100%
Net margin
-733.7%
The net margin has plunged by 115% from the previous quarter
EDIT's operating margin has dropped by 110% since the previous quarter
Editas Medicine's gross profit has plunged by 59% YoY and by 48% from the previous quarter
The revenue has dropped by 59% year-on-year and by 48% since the previous quarter
Growth
What is Editas Medicine's growth rate over time
Valuation
What is Editas Medicine stock price valuation
P/E
N/A
P/B
0.73
P/S
3.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.82
EDIT's EPS is down by 43% year-on-year and by 13% since the previous quarter
EDIT's P/B is 78% below its 5-year quarterly average of 3.1 and 54% below its last 4 quarters average of 1.5
EDIT's equity has dropped by 62% year-on-year and by 24% since the previous quarter
The P/S is 91% less than the 5-year quarterly average of 33.0 and 49% less than the last 4 quarters average of 5.6
The revenue has dropped by 59% year-on-year and by 48% since the previous quarter
Efficiency
How efficient is Editas Medicine business performance
The ROE has plunged by 164% YoY and by 42% from the previous quarter
EDIT's return on sales has dropped by 110% since the previous quarter
Editas Medicine's ROA has plunged by 108% YoY and by 25% from the previous quarter
EDIT's return on invested capital has dropped by 92% year-on-year and by 23% since the previous quarter
Dividends
What is EDIT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EDIT.
Financial health
How did Editas Medicine financials performed over time
EDIT's total assets is 65% higher than its total liabilities
EDIT's total liabilities is up by 38% year-on-year and by 36% since the previous quarter
EDIT's total assets is down by 32% YoY but it is up by 4.3% QoQ
The debt is 31% less than the equity
The debt has soared by 153% YoY and by 140% from the previous quarter
EDIT's equity has dropped by 62% year-on-year and by 24% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.